country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

製品番号: HY-P992535

Copy Link Print Information

JANX-007

JANX-007 is a tumor protease-activated anti-PSMA x CD3 bispecific T cell engager (BiTE). After JANX-007 is cleaved by tumor-specific proteases in the tumor microenvironment to remove the mask, CD3 is exposed, recruiting T cells to kill PSMA-positive tumor cells, and the activated and released TCE fragment can be rapidly cleared. JANX-007 can be used in cancer-related research, such as metastatic castration-resistant prostate cancer.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

保管条件:

Please store the product under the recommended conditions in the Certificate of Analysis.

JANX-007 構造式

価格（税別）

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性
- 製品説明
- Species Reactivity
- 体外実験
- Target
- Conjugated
- アプリケーション
化学情報
純度とドキュメンテーション
参考文献
Calculators
Help & FAQs
関連分類
Bioz

生物活性

製品説明

Species Reactivity

Human

体外実験

JANX-007 exerts its function after tumor protease cleavage of the linker sequence removes the mask and albumin-binding domain, thereby mediating tumor cell killing; the activated TCE fragment released from the tumor is designed to be rapidly cleared in circulation^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Related Protocols :

Target

PSMA & CD3

Conjugated

Unconjugated

アプリケーション

ELISA, FACS, Functional assay

化学情報

SMILES

[JANX-007]
保管条件

Please store the product under the recommended conditions in the Certificate of Analysis.

純度とドキュメンテーション

Inhibitory Antibodies User Guide (603 KB)

参考文献

[1]. Zhang J, et al. Developmental Therapeutics in Metastatic Prostate Cancer: New Targets and New Strategies. Cancers. 2024 Sep 06;16(17):3098.

[2]. Hudson A, et al. A phase 1, first-in-human, dose escalation study of JNJ-80038114, a PSMAxCD3 bispecific antibody, in participants with metastatic castration-resistant prostate cancer. Cancer chemotherapy and pharmacology. 2026 Jan 06;96(1):5.

Calculators

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

お問い合わせ在庫あり

Other size

お問い合わせ